quantcowboy: With all respect, I think you may have missed the point of my counter-point. MYOG was listed on a major exchange and trading in the 20's with a product line. CYCR is a bulletin board issue trading at .33 with bubkus. Shareholders of the buyer would demand the resignation of their BOD and the ransacking of their homes were they to propose an equity purchase of CYCR at this stage. No, the company has now built itself into a box. Only genuine product sales and revenues can save us now. At this point, it may not matter what the company says in EHM or on BusinessWire; fence-sitters will now seek other game in other valleys and LT shareholders are most likely rethinking their stance. All due to the erosion of trust which I have been warning the company about for weeks. A child's misdeed is always compounded by a cover-up lie to shield that misdeed from his parents. Once the two are found out, you're grounded for not one week, but two. The market has seen enough head fakes here this year, and been left asking enough questions, to know this is a watch-and-see. All because of a lack of simple communication and transperancy. You hit on perhaps a key point, yourself. You complimented my ability and willingness to communicate ideas, news, and stock talk. I'm just an investor. A market player. I could have worked for this company for peanuts and given them an amiable human face and voice, a voice of reassurance and assistance. Ah, but I'm not in the club, I guess. All questions have answers. Why is the company not applying for CFDA approval when the Chindia market is such a vital piece of the CYCR puzzle? Why must we dig for roots like hogs for news on message boards which are eventually unearthed and provided by surrogate mouth-pieces on a 30-day delay, from the routine and banal, like the name change, to SEC sensitive and compromising insider information like the status of clinical trials in progress, which all shareholders should be privy to at once, and not just one serf who has found favor in the eyes of His Lordship? How did Diamics move their Tinker Toy version through FDA approval so quickly? The e2 received 510(k) approval for marketing years ago---what exactly is the modification on the handle that requires another year of trials with over 600 patients? Why did the earlier pr explicitely mention a fast track FDA trial with a 45-60 day target time, when nothing could have been further from the truth? No one can say I didn't try to warn these guys. I've been tired a long time, quantcowboy. Now, it appears, so is the market. Let's face it. We are in for a period of extended waiting...and so, we wait.
AI
Market Data 
Markets 
